194669-38-0

Basic information

• Product Name: tert-butyl 4-(2-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-butyl 4-(2-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate;1(2H)-Pyridinecarboxylic acid, 4-(2-cyanophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester
• CAS NO: 194669-38-0
• Molecular Formula: C₁₇H₂₀N₂O₂
• Molecular Weight: 284.3529
• Mol File: 194669-38-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-(2-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(2-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(194669-38-0)
• EPA Substance Registry System: tert-butyl 4-(2-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(194669-38-0)

Safety Data

• Hazardous Substances Data: 194669-38-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
Tert-butyl 4-(2-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate is used as a potential drug candidate for the development of new pharmaceuticals. Its dihydropyridine structure and unique properties make it a valuable compound for exploring its therapeutic potential in various medical conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, tert-butyl 4-(2-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate is used as a subject of research to understand its structure-activity relationships and to optimize its properties for specific therapeutic applications. tert-butyl 4-(2-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate's unique features provide opportunities for the design and synthesis of novel drug molecules with improved efficacy and selectivity.
Used in Drug Delivery Systems:
Tert-butyl 4-(2-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate can be used as a component in drug delivery systems to improve the bioavailability and therapeutic outcomes of other active pharmaceutical ingredients. Its chemical properties may allow for the development of innovative formulations that enhance drug solubility, stability, and targeted delivery to specific tissues or organs.
Used in Chemical Synthesis:
As a dihydropyridine derivative, tert-butyl 4-(2-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate can be used as a starting material or intermediate in the synthesis of other complex organic compounds. Its unique structure and reactivity may enable the development of novel synthetic routes and methodologies for the preparation of pharmaceuticals and other bioactive molecules.

Upstream product

• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 4387-36-4 2-iodobenzonitrile 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 2042-37-7 o-cyanobromobenzene 
• 138642-62-3 2-Cyanophenylboronic acid 
• 148651-34-7 iodo(2-cyanophenyl)zinc 

Downstream Products

• 256951-72-1 tert-butyl 4-(2-cyanophenyl)piperidine-1-carboxylate 
• 304462-63-3 2-(piperidin-4-yl)benzonitrile 
• 1394387-80-4 2-(1-(2-((3-isopropylisoxazol-5-yl)methylamino)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile 
• 1574730-66-7 2-(1-(2-aminoethyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile 
• 1574730-92-9 2-(1-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile 
• 256951-73-2 2-(piperidin-4-yl)benzonitrile hydrochloride 
• 256951-74-3 2-[1-(3-tert-butoxycarbonylaminopropyl)-piperidin-4-yl] benzonitrile 

Relevant articles and documents

PHENYL mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Synthesis and biological evaluation of 1-(isoxazol-5-ylmethylaminoethyl)-4- phenyl tetrahydropyridine and piperidine derivatives as potent T-type calcium channel blockers with antinociceptive effect in a neuropathic pain model

New tetrahydropyridinyl and piperidinyl ethylamine derivatives were designed with hypothetical mapping on pharmacophore model generated from ligand-based virtual screening. The designed compounds were synthesized, and their inhibitory activities on T-type calcium channel were assayed using FDSS and patch-clamp assay. Among them, compounds 7b and 10b showed potent T-type calcium current blocking activity against Cav3.1 (α 1G) and Cav3.2 (α1H) channel simultaneously. With hERG and pharmacokinetics studies, compounds 7b and 10b were evaluated for the antinociceptive effect on rat model of neuropathic pain. They were significantly effective in decreasing the pain responses to mechanical and cold allodynia induced by spinal nerve ligation. These results suggest that modulation of α1G and α1H subtype T-type calcium channels may provide a promising approach for the treatment of neuropathic pain.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein X1, X2, W, R1 to R5, L and m have the meaning according to the claims, are glucosidase inhibitors, and can be employed, inter alia, for the treatment of Alzheimer's disease.

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

Alpha 1A adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Oxazolidinones useful as alpha 1a adrenoceptor antagonists

Novel hydroxymethyl- and alkoxymethyl-oxazolidinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists

Novel dihydropyridinone and pyrrolinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha1aadrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha1areceptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

Oxazolidinones useful as alpha 1A adrenoceptor antagonists

Novel oxazolidinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.

A series of alpha1a receptor antagonists derived from a 4-aryl-3,4-dihydropyridine-2-one heterocycle is disclosed. Potency in the low nanomolar to picomolar range along with high selectivity was obtained. In vivo efficacy in a prostate contraction model in rats was observed with a few derivatives.

In vitro, and in vivo, evaluation of dihydropyrimidinone C-5 amides as potent and selective α(1A) receptor antagonists for the treatment of benign prostatic hyperplasia

α1 Adrenergic receptors mediate both vascular and lower urinary tract tone, and α1 receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified, with the α(1A) receptor being most prevalent in lower urinary tract tissue. This paper explores 4-aryldihydropyrimidinones attached to an aminopropyl-4- arylpiperidine via a C-5 amide as selective α(1A) receptor subtype antagonists. In receptor binding assays, these types of compounds generally display K(i) values for the α(1a) receptor subtype 20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the α(1a) over the α(1b) and α(1d) receptors as well as its favorable pharmacokinetic profile, 48 has the potential to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.